Proteomics

Dataset Information

0

A proteomics workflow reveals predictive autoantigens in idiopathic pulmonary fibrosis (cohort 2)


ABSTRACT: Rationale: The diagnosis of idiopathic pulmonary fibrosis (IPF) requires exclusion of an underlying autoimmune disease, as present in interstitial lung diseases associated with connective tissue diseases (CTD-ILD). The prevalence of autoantibodies in IPF patients is currently unknown. Objectives: An unbiased assay for de novo discovery of autoantigens can help characterizing autoreactivities in IPF patients beyond clinically established autoimmune panels. Methods: We developed the proteomic Differential Antigen Capture (DAC) assay, capturing patient antibodies from plasma, followed by affinity purification coupled to mass spectrometry (AP-MS). The DAC assay quantifies the binding capacity of patient antibodies to proteins in a pooled native extract from lung explants (ILD explants n=41; donor controls n=12). Plasma antibodies from patients with IPF (n=35), CTD-ILD (n=24) and age-matched controls (n=32) were analyzed and validated in an independent cohort (IPF: n=40; CTD-ILD: n=20). Plasma antibody binding profiles were associated with clinical meta-data including diagnosis, lung function and transplant free survival. Measurements and Main Results: We identified 586 putative autoantigens in both study cohorts with a broad heterogeneity among disease entities and cohorts. On average, in IPF a mean±SD of 16±40 autoantigens and in CTD-ILD a mean±SD of 9±15 autoantigens were identified per patient. We identified 18 IPF-specific autoantigens validated in the second cohort. Interestingly, there was also a high number of shared autoantigens in IPF and CTD-ILD patients, with 17 being present in IPF and CTD-ILD of both cohorts. Presence of antibodies to Thrombospondin 1 (THBS1) and tubulin beta-1 chain (TUBB1) was associated with a significantly reduced survival in patients with IPF (p=0.002 and p=0.019, respectively). This signature was often associated with autoreactivity against talin-1 (TLN1), latent-transforming growth factor beta-binding protein 1 (LTBP1), epididymis secretory protein Li 112 (HEL-S-112), zyxin (ZYX), the LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1) and caldesmon (CALD1). Conclusions: Unbiased proteomic profiling reveals that the overall prevalence of autoantibodies is similar in IPF and CTD-ILD patients and identifies novel IPF specific autoantigens associated with patient survival.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma, Lung

SUBMITTER: Christoph Mayr  

LAB HEAD: Herbert Schiller

PROVIDER: PXD024123 | Pride | 2021-02-22

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
20171102_QX7_ChMa_SA_Ctr-10_1.raw Raw
20171102_QX7_ChMa_SA_Ctr-10_2.raw Raw
20171102_QX7_ChMa_SA_Ctr-10_3.raw Raw
20171102_QX7_ChMa_SA_Ctr-11_1.raw Raw
20171102_QX7_ChMa_SA_Ctr-11_2.raw Raw
Items per page:
1 - 5 of 299

Similar Datasets

2021-02-22 | PXD024113 | Pride
2021-03-30 | GSE156310 | GEO
2022-01-05 | GSE192985 | GEO
2024-10-23 | GSE267652 | GEO
| EGAD00001011334 | EGA
2020-12-15 | GSE159354 | GEO
| PRJNA967308 | ENA
2024-07-10 | GSE239664 | GEO
2011-03-24 | E-GEOD-21369 | biostudies-arrayexpress
2011-04-19 | E-GEOD-21394 | biostudies-arrayexpress